Novo Doubles Down on Oral Obesity Meds With Septerna Deal Worth up to $2.4B

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with Septerna to put new discovery-stage programs into play.